<DOC>
	<DOCNO>NCT01378273</DOCNO>
	<brief_summary>Recombinant human erythropoietin ( Epo ) promise novel neuroprotective agent . Epo decrease neuronal program cell death result brain injury ; anti-inflammatory effect , increase neurogenesis , protect oligodendrocytes injury . We hypothesize neonatal Epo treatment ELGANs decrease combine outcome death severe NDI 40 % 30 % ( primary outcome ) , combine outcome death plus moderate severe NDI 60 % 40 % ( secondary outcome ) measure 24-26 month correct age . 1 . To determine whether Epo decrease combine outcome death NDI 24-26 month correct age . NDI define presence one following : CP , Bayley Scales Infant Toddler Development , 3rd Edition ( Bayley-III ) Cognitive Scale &lt; 70 ( severe , 2 SD mean ) 85 ( moderate , 1 SD mean ) . CP diagnose classified standardized neurologic exam , severity classify Gross Motor Function Classification System ( GMFCS ) . 2 . To determine whether risk Epo administration ELGANs examine , blind manner , Epo-related safety measure compare infant receive Epo give placebo . 3 . To test whether Epo treatment decrease serial measure circulate inflammatory mediator , biomarkers brain injury . 4 . To compare brain structure ( measure MRI ) Epo treatment control group 36 week PMA . MRI assessment include documentation intraventricular hemorrhage ( IVH ) , white matter injury ( WMI ) hydrocephalus ( HC ) , volume total deep gray matter , white matter cerebellum , brain gyrification , tract-based spatial statistic ( TBSS base diffusion tensor image ) . As exploratory aim , determine MRI measurement best predict neurodevelopment ( CP , cognitive motor scale ) 24-26 month correct age . Anticipated outcome : Early Epo treatment ELGANs decrease biochemical MRI marker brain injury , safe , confer improved neurodevelopmental outcome 24-26 month correct age compare placebo , provide much-needed therapy group vulnerable infant .</brief_summary>
	<brief_title>Preterm Erythropoietin Neuroprotection Trial ( PENUT Trial )</brief_title>
	<detailed_description>This randomize , placebo-controlled , study Epo treatment preterm infant 24-0/7 27-6/7 week gestation , begin first 24 hour birth . Randomization stratify site gestational age birth ( &lt; 26 week 26-27-6/7 ) . Study size sample 940 patient . We expect evaluate 752 subject 24-26 month correct age , primary endpoint . There enrollment restriction base gender , ethnicity race . Enrollment expect take 24-26 month , subject participate 24-26 month correct age neurodevelopmental outcome assess . The combined outcome death severe NDI compare Epo-treated control subject . All outcomes collect blind manner . Subjects randomize data-coordinating center ( DCC ) Epo treatment placebo , Epo treatment continue 32-6/7 week post menstrual age . Serial measurement circulate inflammatory mediator biomarkers brain injury make . A brain MRI do 36 week post menstrual age subset infant . Phone contact occur 4 , 8 , 12 , 18 month . Face face follow occur 24-26 month correct age . The primary outcome death severe NDI 24-26 month correct age , secondary outcome death moderate NDI . Our primary sample size calculation base conservative assumption Epo treatment result 40 % reduction severe NDI rate ( range animal study 49-70 % ) minimal impact death . This would yield control group rate primary outcome 40.4 % expect treated rate 31.5 % thus yield 8.9 % low rate Death + NDI .</detailed_description>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>1 . NICU inpatients 240/7 276/7 week gestation 2 . Less twenty four hour age 3 . Parental inform consent 1 . Major lifethreatening anomaly ( brain , cardiac , chromosomal anomaly ) 2 . Hematologic crises DIC , hemolysis due blood group incompatibilities 3 . Polycythemia ( hematocrit &gt; 65 ) 4 . Congenital infection</criteria>
	<gender>All</gender>
	<minimum_age>24 Weeks</minimum_age>
	<maximum_age>27 Weeks</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>neuroprotection</keyword>
	<keyword>erythropoietin</keyword>
	<keyword>Epo</keyword>
	<keyword>ELGANs</keyword>
	<keyword>preterm</keyword>
	<keyword>neonate</keyword>
</DOC>